<DOC>
	<DOCNO>NCT02997969</DOCNO>
	<brief_summary>The purpose study evaluate safety immune response HIV clade C DNA vaccine MF59-adjuvanted clade C Env protein healthy , HIV-uninfected adult .</brief_summary>
	<brief_title>Safety Immune Response Clade C DNA HIV Vaccine</brief_title>
	<detailed_description>This study evaluate safety , tolerability , immunogenicity DNA-HIV-PT123 ( HIV clade C DNA vaccine ) Bivalent Subtype C gp120/MF59 healthy , HIV-uninfected adult . The study enroll healthy , HIV-uninfected participant age 18 40 year . Participants randomly assign one 6 group . Each group receive experimental vaccine protein and/or placebo 4 study visit . Participants Groups 1-3 receive injection via needle syringe . Participants Groups 4-6 receive DNA vaccine via Biojector , protein and/or placebo via needle syringe . Participants Groups 1 4 receive DNA vaccine month 0 , 1 , 3 , 6 protein month 3 6 . Participants Groups 2 5 receive DNA vaccine protein month 0 , 1 , 6 placebo month 3 . Participants Groups 3 6 receive placebo month 0 , 1 , 3 , 6 . Study visit include physical examination , interview and/or questionnaire , HIV test HIV risk-reduction counseling , urine blood collection . Participants may optionally choose provide rectal fluid , cervical fluid , semen sample .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>General Demographic Criteria Age 18 40 year Access participate HVTN CRS willingness follow plan duration study Ability willingness provide inform consent Assessment understanding : volunteer demonstrate understand study ; provide answer questionnaire prior first vaccination verbal demonstration understand questionnaire item answer incorrectly Agrees enroll another study investigational research agent Good general health show medical history , physical exam , screen laboratory test HIVRelated Criteria : Willingness receive HIV test result Willingness discuss HIV infection risk amenable HIV risk reduction counsel . Assessed clinic staff `` low risk '' HIV infection commit maintain behavior consistent low risk HIV exposure last require protocol clinic visit . Laboratory Inclusion Values : Hemogram/Complete blood count ( CBC ) Hemoglobin ≥ 11.0 g/dL volunteer bear female , ≥ 13.0 g/dL volunteer bear male White blood cell count = 3,300 12,000 cells/mm^3 Total lymphocyte count ≥ 800 cells/mm^3 Remaining differential either within institutional normal range site physician approval Platelets = 125,000 550,000/mm^3 Chemistry Chemistry panel : ALT , AST , ALP &lt; 1.25 time institutional upper limit normal ; creatinine ≤ institutional upper limit normal . Virology Negative HIV1 2 blood test : Sites may use locally available assay approve HVTN Laboratory Operations . Negative Hepatitis B surface antigen ( HBsAg ) Negative antiHepatitis C virus antibody ( antiHCV ) , negative HCV polymerase chain reaction ( PCR ) antiHCV positive Urine Normal urine : Negative urine glucose , Negative trace urine protein , Negative trace urine hemoglobin ( trace hemoglobin present dipstick , microscopic urinalysis red blood cell level within institutional normal range ) . Reproductive Status Volunteers bear female : negative serum urine beta human chorionic gonadotropin ( βHCG ) pregnancy test perform prior vaccination day initial vaccination . Persons NOT reproductive potential due undergone total hysterectomy bilateral oophorectomy ( verified medical record ) , require undergo pregnancy test . Reproductive status : A volunteer bear female must : Agree consistently use effective contraception ( Appendix B ) sexual activity could lead pregnancy least 21 day prior enrollment last require protocol clinic visit . Effective contraception define use 1 follow method : Condoms ( male female ) , Diaphragm cervical cap , PLUS 1 follow method : Intrauterine device ( IUD ) , Hormonal contraception ( accordance applicable national contraception guideline ) , Successful vasectomy male partner ( consider successful volunteer report male partner [ 1 ] documentation azoospermia microscopy , [ 2 ] vasectomy 2 year ago resultant pregnancy despite sexual activity vasectomy ) ; Any contraceptive method approve HVTN 111 PSRT Or reproductive potential , reach menopause ( menses 1 year ) undergone hysterectomy , bilateral oophorectomy , tubal ligation ; Or sexually abstinent . Volunteers born female must also agree seek pregnancy alternative method , artificial insemination vitro fertilization last require protocol clinic visit Other Volunteers 21 year age old bear female consent provide cervical sample : pap smear within 3 year prior enrollment , late result report normal ASCUS ( atypical squamous cell undetermined significance ) ; 21 year old pap smear within last 3 year prior enrollment , must willing undergo pap smear result report normal ASCUS prior sample collection . General Blood product receive within 120 day first vaccination Investigational research agent receive within 30 day first vaccination Body mass index ( BMI ) ≥ 40 ; BMI ≥ 35 2 following : systolic blood pressure &gt; 140 mm Hg , diastolic blood pressure &gt; 90 mm Hg , current smoker , know hyperlipidemia Intent participate another study investigational research agent plan duration HVTN 111 study Pregnant breastfeeding Vaccines Injections HIV vaccine ( ) receive prior HIV vaccine trial . For volunteer receive control/placebo HIV vaccine trial , HVTN 111 PSRT determine eligibility casebycase basis . NonHIV experimental vaccine ( ) receive within last 5 year prior vaccine trial . Exceptions may make vaccine subsequently undergone licensure FDA . For volunteer receive control/placebo experimental vaccine trial , HVTN 111 PSRT determine eligibility casebycase basis . For volunteer receive experimental vaccine ( ) great 5 year ago , eligibility enrollment determine HVTN 111 PSRT casebycase basis . Live attenuate vaccine influenza vaccine receive within 30 day first vaccination schedule within 14 day injection ( eg , measles , mumps , rubella [ MMR ] ; oral polio vaccine [ OPV ] ; varicella ; yellow fever ) Influenza vaccine vaccine live attenuate vaccine receive within 14 day prior first vaccination ( eg , tetanus , pneumococcal , Hepatitis A B ) Allergy treatment antigen injection within 30 day first vaccination schedule within 14 day first vaccination Immune System Immunosuppressive medication receive within 168 day first vaccination . ( Not exclude participation : [ 1 ] corticosteroid nasal spray ; [ 2 ] inhaled corticosteroid ; [ 3 ] topical corticosteroid mild , uncomplicated dermatitis ; [ 4 ] single course oral/parenteral corticosteroid dose &lt; 2 mg/kg/day length therapy &lt; 11 day completion least 30 day prior enrollment . Serious adverse reaction vaccine vaccine component egg , egg product , neomycin , include history anaphylaxis relate symptom hive , respiratory difficulty , angioedema , and/or abdominal pain . ( Not exclude : volunteer nonanaphylactic adverse reaction pertussis vaccine child . ) Immunoglobulin receive within 60 day first vaccination Autoimmune disease Immunodeficiency Clinically significant medical condition Untreated incompletely treat syphilis infection Clinically significant medical condition , physical examination finding , clinically significant abnormal laboratory result , past medical history clinically significant implication current health . A clinically significant condition process include limit : A process would affect immune response , A process would require medication affect immune response , Any contraindication repeat injection blood draw , A condition require active medical intervention monitoring avert grave danger volunteer 's health wellbeing study period , A condition process sign symptom could confuse reaction vaccine , Any condition specifically list among exclusion criterion . Any medical , psychiatric , occupational , condition , judgment investigator , would interfere , serve contraindication , protocol adherence , assessment safety reactogenicity , volunteer 's ability give inform consent Psychiatric condition precludes compliance protocol . Specifically excluded person psychosis within past 3 year , ongoing risk suicide , history suicide attempt gesture within past 3 year . Current antituberculosis ( TB ) prophylaxis therapy Asthma mild , wellcontrolled asthma . ( Symptoms asthma severity define recent National Asthma Education Prevention Program ( NAEPP ) Expert Panel report ) . Exclude volunteer : Uses shortacting rescue inhaler ( typically beta 2 agonist ) daily , Uses moderate/high dose inhaled corticosteroid , In past year either follow : Greater 1 exacerbation symptom treat oral/parenteral corticosteroid ; Needed emergency care , urgent care , hospitalization , intubation asthma . Diabetes mellitus type 1 type 2 , include case control diet alone . ( Not exclude : history isolate gestational diabetes . ) Thyroidectomy , thyroid disease require medication last 12 month Hypertension : If person find elevate blood pressure hypertension screen previously , exclude blood pressure well control . Wellcontrolled blood pressure define consistently ≤ 140 mm Hg systolic ≤ 90 mm Hg diastolic , without medication , isolate , brief instance high reading , must ≤ 150 mm Hg systolic ≤ 100 mm Hg diastolic . For volunteer , blood pressure must ≤ 140 mm Hg systolic ≤ 90 mm Hg diastolic enrollment . If person NOT find elevate blood pressure hypertension screen previously , exclude systolic blood pressure ≥ 150 mm Hg enrollment diastolic blood pressure ≥ 100 mm Hg enrollment . Bleeding disorder diagnose doctor ( eg , factor deficiency , coagulopathy , platelet disorder require special precaution ) Malignancy ( Not exclude : Volunteer malignancy excise surgically , investigator 's estimation , reasonable assurance sustain cure . unlikely experience recurrence malignancy period study ) Seizure disorder : History seizure ( ) within past three year . Also exclude volunteer use medication order prevent treat seizure ( ) time within past 3 year . Asplenia : condition result absence functional spleen History hereditary angioedema , acquire angioedema , idiopathic angioedema .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV</keyword>
</DOC>